Operator preference and determinants of size selection when additional intermediate-size aortic transcatheter heart valves are made available.
Volume
338
Pagination
168 - 173
DOI
10.1016/j.ijcard.2021.06.029
Journal
Int J Cardiol
Metadata
Show full item recordAbstract
BACKGROUND: Appropriate size selection of transcatheter heart valves (THVs) is fundamental to reduce transcatheter aortic valve implantation (TAVI) related complications, particularly paravalvular aortic regurgitation, new permanent pacemaker implantation, and annular rupture. We sought to investigate the frequency of operator selection of intermediate-size balloon-expandable Myval THVs (Meril Life Sciences Pvt. Ltd., India) for TAVI in a real-world dataset. METHODS: In this retrospective survey of patients treated with TAVI using the Myval THV, 20, 23, 26, and 29 mm are conventional-size THVs, 21.5, 24.5 and 27.5 mm are intermediate-size THVs, and 30.5 and 32 mm are extra-large THVs. Operator size selection for implantation was based on multislice computed tomography (MSCT) derived aortic-root dimensions. RESULTS: A total of 1115 patients underwent Myval THV implantation in 27 countries worldwide. The Myval intermediate-size THVs were used in 468 (42.0%) patients. MSCT data were available in 562 patients. There was no statistical difference between the Intermediate/Upsized and Appropriately sized groups or Intermediate/Downsized and Appropriately sized groups in terms of different variables measured with MSCT except for annular dimensions and degree of calcification. CONCLUSIONS: Intermediate-size Myval balloon-expandable THVs are used in nearly half of all cases in contemporary real-world TAVI practice, addressing the unmet need of TAVI operators for a more calibrated THV choice. Our hypothesis should be tested in randomized prospective studies currently initiated in Europe, including clinical outcomes of patients treated with both conventional- and intermediate-size THVs.
Authors
Kawashima, H; Serruys, PW; Mylotte, D; Rosseel, L; Amat-Santos, IJ; Rao, RS; Onuma, Y; Wijns, W; Abdel-Wahab, M; Baumbach, ACollections
Language
Licence information
The following license files are associated with this item:
Related items
Showing items related by title, author, creator and subject.
-
Aortic valve and left ventricular outflow tract calcium volume and distribution in transcatheter aortic valve replacement: Influence on the risk of significant paravalvular regurgitation
Hansson, NC; Leipsic, J; Pughese, F; Andersen, HR; Rossi, A; Simonato, M; Jensen, KT; Christiansen, EH; Terkelsen, CJ; Blanke, P (2018) -
Adjunctive Antithrombotic Therapy for Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement.
Saito, Y; Nazif, T; Baumbach, A; Tchétché, D; Latib, A; Kaple, R; Forrest, J; Prendergast, B; Lansky, A (American Medical Association, 2019-11-13)Importance: Transcatheter aortic valve replacement (TAVR) is an established alternative to surgery for patients with severe symptomatic aortic stenosis. Adjunctive antithrombotic therapy used to mitigate thrombotic risks ... -
Transcatheter aortic valve implantation in acute decompensated aortic stenosis
Patel, K; Broyd, C; Chehab, O; Jerrum, M; Queenan, H; Bedford, K; Barakat, F; Kennon, S; Ozkor, M; Mathur, A (2020-09-01)